Long‐term experience with imatinib therapy in chronic phase chronic myelogenous leukemia—Remarkable activity with room for improvement

Abstract

American Journal of HematologyVolume 83, Issue 3 p. 175-177 Editorial and PerspectiveFree Access Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia—Remarkable activity with room for improvement Ayalew Tefferi, Corresponding Author Ayalew Tefferi [email protected] Mayo Clinic, Rochester, Minnesota MD Anderson Cancer Center, Houston, TexasDivision of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905Search for more papers by this authorHagop Kantarjian, Hagop Kantarjian Mayo Clinic, Rochester, Minnesota MD Anderson Cancer Center, Houston, TexasSearch for more papers by this author Ayalew Tefferi, Corresponding Author Ayalew Tefferi [email protected] Mayo Clinic, Rochester, Minnesota MD Anderson Cancer Center, Houston, TexasDivision of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905Search for more papers by this authorHagop Kantarjian, Hagop Kantarjian Mayo Clinic, Rochester, Minnesota MD Anderson Cancer Center, Houston, TexasSearch for more papers by this author First published: 07 January 2008 https://doi.org/10.1002/ajh.21136Citations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Virchow R. Weisses Blut. Froriep's Notzien 1845; 36: 151– 156. 2 Nowell PC,Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. J Natl Cancer Inst 1960; 25: 85. 3 Druker BJ,Talpaz M,Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031– 1037. 4 Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290– 293. 5 Fialkow PJ,Gartler SM,Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 1967; 58: 1468– 1471. 6 de Klein A,van Kessel AG,Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765– 767. 7 Groffen J,Stephenson JR,Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93– 99. 8 Heisterkamp N,Stam K,Groffen J, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985; 315: 758– 761. 9 Ben-Neriah Y,Daley GQ,Mes-Masson AM,Witte ON,Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212– 214. 10 Konopka JB,Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116– 3123. 11 Lugo TG,Pendergast AM,Muller AJ,Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079– 1082. 12 Kelliher MA,McLaughlin J,Witte ON,Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990; 87: 6649– 6653. 13 Daley GQ,Van Etten RA,Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824– 830. 14 Pendergast AM,Muller AJ,Havlik MH,Maru Y,Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991; 66: 161– 171. 15 Sattler M,Salgia R,Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996; 12: 839– 846. 16 Gishizky ML,Johnson-White J,Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993; 90: 3755– 3759. 17 Pear WS,Miller JP,Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780– 3792. 18 Li S,Ilaria RLJr,Million RP,Daley GQ,Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399– 1412. 19 Druker BJ,Tamura S,Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561– 566. 20 Buchdunger E,Zimmermann J,Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100– 104. 21 Buchdunger E,Zimmermann J,Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995; 92: 2558– 2562. 22 Okuda K,Weisberg E,Gilliland DG,Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440– 2448. 23 Heinrich MC,Griffith DJ,Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925– 932. 24 Schindler T,Bornmann W,Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938– 1942. 25 Druker BJ,Sawyers CL,Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038– 1042. 26 Kantarjian H,Sawyers C,Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645– 652. 27 Talpaz M,Silver RT,Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928– 1937. 28 Sawyers CL,Hochhaus A,Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530– 3539. 29 Kantarjian HM,Cortes J,O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547– 3553. 30 Kantarjian HM,O'Brien S,Cortes JE, et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167– 2176. 31 Ottmann OG,Druker BJ,Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965– 1971. 32 van Oosterom AT,Judson I,Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358: 1421– 1423. 33 Demetri GD,von Mehren M,Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472– 480. 34 Gleich GJ,Leiferman KM,Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577– 1578. 35 Cools J,DeAngelo DJ,Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201– 1214. 36 Apperley JF,Gardembas M,Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481– 487. 37 Pardanani A,Reeder T,Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391– 3397. 38 Pardanani A,Elliott M,Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535– 536. 39 Pardanani A,Ketterling RP,Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 2003; 102: 3093– 3096. 40 Pardanani A,Brockman SR,Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038– 3045. 41 Baccarani M,Saglio G,Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809– 1820. 42 Goldman JM. Treatment of chronic myeloid leukaemia: Lessons and challenges. Int J Hematol. 2002; 76 Suppl 2: 189– 192. 43 Maziarz RT,Mauro MJ. Transplantation for chronic myelogenous leukemia: Yes, no, maybe so… An Oregon perspective. Bone Marrow Transplant 2003; 32: 459– 469. 44 Kantarjian HM,Giles FJ,O'Brien S,Giralt S,Talpaz M. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer 2000; 89: 1647– 1658. 45 van Rhee F,Szydlo RM,Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553– 560. 46 The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541– 1548. 47 The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820– 825. 48 Kantarjian HM,O'Brien S,Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033– 1041. 49 Guilhot F,Chastang C,Michallet M, et al. for the French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223– 229. 50 Baccarani M,Rosti G,de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99: 1527– 1535. 51 O'Brien SG,Guilhot F,Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994– 1004. 52 Druker BJ,Guilhot F,O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408– 2417. 53 Kantarjian HM,Talpaz M,O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835– 1840. 54 Roy L,Guilhot J,Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood 2006; 108: 1478– 1484. 55 Hochhaus A,Druker B,Sawyers C, et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood %R 101182/blood-2007-07-103523. 2007:blood-2007-2007-103523. 56 Iacobucci I,Rosti G,Amabile M, et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 2006; 24: 454– 459. 57 Atallah E,Kantarjian H,Cortes J. Emerging safety issues with imatinib and other abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007; 7 ( Suppl 3): S105– S112. 58 Quintas-Cardama A,Kantarjian H,Cortes J. Flying under the radar: The new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834– 848. Citing Literature Volume83, Issue3March 2008Pages 175-177 ReferencesRelatedInformation